Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeted CAR-T cells for Recurrent or Refractory DLBCL
NCT02728882Phase 2Unknown
- Sponsor
- Sinobioway Group Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of Sino19 in diffuse large B-cell lymphoma (DLBCL), sponsored by Sinobioway Group Co., Ltd.. Status: unknown.
02
Drugs
Sino19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02728882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728882.